Company Encyclopedia
View More
name
908 Devices
MASS.US
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices for use in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. Its products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as process fingerprint data to support large-scale efforts in predictive bioprocess modeling. The company’s products comprise Maven, an on-line device for bioprocess monitoring and control; Trace C2, an on-line monitoring of methanol or ethanol and control of substrate feeding in fermentation processes; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. It operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of Americas.
659.24 B
MASS.USMarket value -Rank by Market Cap -/-

Financial Score

20/11/2025 Update
C
Electronic Equipment and InstrumentsIndustry
Industry Ranking52/102
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-54.42%E
    • Profit Margin-6.35%D
    • Gross Margin52.52%B
  • Growth ScoreA
    • Revenue YoY36.21%A
    • Net Profit YoY93.14%A
    • Total Assets YoY7.06%B
    • Net Assets YoY4.01%C
  • Cash ScoreC
    • Cash Flow Margin-1574.56%E
    • OCF YoY36.21%A
  • Operating ScoreD
    • Turnover0.35D
  • Debt ScoreB
    • Gearing Ratio28.59%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Positive Trajectory and Growth Prospects: Buy Rating for 908 Devices

    TD Cowen analyst Brendan Smith has reiterated a Buy rating for 908 Devices, citing strong third-quarter performance and maintained revenue guidance for fiscal year 2025. The company's restructuring efforts and the successful launch of the VipIR product are expected to drive future growth. 908 Devices aims for positive adjusted EBITDA by Q4 2025 and cash flow breakeven by FY 2026, enhancing its attractiveness to investors.

    Tip Ranks·
    US
    MASS
    +4.67%
    Tip Ranks·
    US
    MASS
    +4.67%

    908 Devices | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 14.01 M

    LB filings·
    US
    MASS
    +4.67%
    LB filings·
    US
    MASS
    +4.67%

    908 Devices | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 14.01 M

    LB filings·
    US
    MASS
    +4.67%
    LB filings·
    US
    MASS
    +4.67%

    Handheld analyzer maker 908 Devices Inc's Q3 revenue beats estimates

    908 Devices Inc reported Q3 revenue of $14 million, exceeding analyst expectations of $13.60 million despite a 4% year-over-year decline. The adjusted EBITDA loss improved by 53% quarter-over-quarter, but the net loss of $15 million missed estimates. The company forecasts full-year 2025 revenue between $54 million and $56 million, with potential impacts from a U.S. Government shutdown. Analyst ratings are strong, with a median 12-month price target of $10.00, reflecting a 26.2% upside from the recent closing price of $7.38.

    Reuters·
    US
    MASS
    +4.67%
    Reuters·
    US
    MASS
    +4.67%

    908 Devices (Nasdaq: MASS) reports Q3 2025 financial results and reiterates 2025 revenue outlook, CEO notes progress.

    In Boston, 908 Devices Inc. announced their financial results for the quarter ending September 30, 2025. The company, traded under Nasdaq as MASS, specializes in handheld chemical analysis tools for health, safety, and defense technology purposes. CEO and Co-founder Kevin J. Knopp expressed satisfaction with their progress so far in the year, highlighting efforts to establish a more stable and lucrative business model and advance their 908 Devices 2.0 vision. Specific revenue numbers were not disclosed.

    Unusual Whales·
    US
    MASS
    +4.67%
    Unusual Whales·
    US
    MASS
    +4.67%
    Posts
    View More